By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is bearish on Merck's current valuation, citing Keytruda's looming patent cliff, the uncertainty around Winrevair's market capture, and the potential acceleration of revenue compression due to biosimilars seeking FDA interchangeability status.
Risk: Accelerated revenue compression due to biosimilars seeking FDA interchangeability status for Keytruda before 2028.
Opportunity: Winrevair becoming a $5B+ revenue driver by 2028, expanding the PAH market to $5B+ peak sales.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and Merck & Co., Inc. (NYSE:MRK) ranks 6th on this list.
It is no secret that the pharmaceutical industry is facing a super-cliff of patent expirations, Merck & Co., Inc. (NYSE:MRK) has successfully de-risked its future by diversifying its oncology portfolio and scaling its multi-billion dollar cardiovascular and vaccine franchises. Elite investors are treating the stock as a growth play due to the launch of Winrevair. Recently released data from the CADENCE trial provided definitive proof-of-concept for Winrevair in treating heart failure with preserved ejection fraction. Analysts predict this drug could capture 2-3 times its original market target, turning it into a $5 billion+ annual revenue powerhouse by 2028. This success is vital because it provides high-margin growth that is entirely independent of Merck’s flagship drug, Keytruda.
Merck & Co., Inc. (NYSE:MRK) continues to report double-digit international growth for its HPV vaccine, Gardasil. New long-term efficacy data presented at the EUROGIN 2026 Congress reinforced its status as a non-optional global health utility. Earlier this month, the European Commission approved ENFLONSIA for RSV prevention in infants, positioning Merck to capture a significant share of the multi-billion dollar RSV immunization market. The firm maintains a massive cash flow and a low Beta of 0.26. It is a favorite for income-focused funds, currently trading with a forward P/E of roughly 20x.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Merck’s current 20x forward P/E overestimates the company's ability to seamlessly offset the massive revenue loss from Keytruda’s 2028 patent expiration."
Merck’s valuation at 20x forward P/E (price-to-earnings ratio) is aggressive for a company facing a looming Keytruda patent cliff in 2028. While the article highlights Winrevair and Gardasil, it ignores the extreme concentration risk; Keytruda accounts for roughly 40% of total revenue. Investors are essentially paying a premium for a 'bridge' strategy that relies on the flawless execution of late-stage pipeline assets. If the CADENCE trial data for Winrevair faces regulatory pushback or if pricing pressure in the EU intensifies for Gardasil, the stock’s low beta (volatility relative to the market) will offer little protection against a significant multiple compression.
The market may be correctly pricing in a 'best-in-class' execution scenario, where Merck’s massive free cash flow allows for aggressive M&A to plug the revenue gap before Keytruda loses exclusivity.
"Winrevair's HFpEF expansion provides high-margin growth to offset Keytruda's looming cliff, supporting 12%+ EPS CAGR through 2028."
Merck (MRK) merits its low-risk growth label: Winrevair's CADENCE trial proof-of-concept in HFpEF could expand its $2-3B PAH market to $5B+ peak sales by 2028, independent of Keytruda (42% of 2023 revenue). Gardasil's double-digit international growth (ex-China slowdown) and ENFLONSIA's EU approval tap multi-billion RSV/HPV markets. At 20x forward P/E (vs. 12% EPS CAGR consensus), 0.26 beta, and $17B FCF, it funds 3% yield plus buybacks. De-risks patent cliff via 30%+ oncology diversification.
Keytruda's 2028 patent expiry risks a 20-30% revenue drop from biosimilars, while Winrevair's HFpEF uptake faces reimbursement delays and competition from United Therapeutics' similar assets.
"MRK is a defensive income-plus-optionality play, not a high-growth stock; the Winrevair bull case is real but already priced in, leaving little room for disappointment."
MRK's narrative hinges on Winrevair becoming a $5B+ revenue driver by 2028, but the article conflates CADENCE trial success with market capture certainty. HFpEF is a real market, but 2-3x upside on 'original targets' is vague—what were those targets? The 20x forward P/E already prices in material Winrevair success; there's limited margin of safety if adoption lags or competition emerges. Gardasil growth is real but mature in developed markets. The 0.26 beta and cash flow are genuine defensive strengths, but calling this 'high growth' when Keytruda faces biosimilar pressure post-2028 requires Winrevair, RSV (ENFLONSIA), and pipeline wins all executing flawlessly. Patent cliff risk is real, not 'de-risked.'
If Winrevair captures only 50-60% of the optimistic $5B target due to physician adoption friction or competing HFpEF therapies, and if Gardasil growth plateaus in developed markets faster than expected, MRK's 20x multiple becomes indefensible relative to true growth rates.
"MRK's upside largely rests on one late-stage asset delivering blockbuster revenue; without it, current valuation may not be justified."
The piece frames MRK as a low-risk growth stock due to a diversified portfolio (oncology, cardiovascular, vaccines) and a flashy late-stage asset (Winrevair) alongside steady HPV vaccine momentum and an RSV candidate. Key risk gaps to test: HFpEF has been notoriously hard to monetize; CADENCE results, even if positive, may not translate into multi-year, payer-friendly uptake. The $5B/year target by 2028 for Winrevair would require sustained strong market share, favorable pricing, and clearance of competition. Valuation (~20x forward P/E) looks rich if growth surprises stall, regulatory hurdles emerge for RSV/other franchises, or Keytruda’s IP moat weakens sooner than expected.
Even if Winrevair clears hurdles, HFpEF markets are price-sensitive and slow to scale; the upside thesis hinges on a single asset succeeding in a crowded, competitive space—risk the rest of the portfolio carries and the stock could re-rate on missed milestones.
"Merck's current valuation ignores the inevitable margin compression required to fund the R&D needed to replace Keytruda's massive revenue share."
Grok, your focus on the 30% oncology diversification is misleading. That figure relies on current revenue, not the 2028 cliff reality. Even with Winrevair, Merck’s pipeline lacks a 'blockbuster' replacement for Keytruda’s scale. You’re ignoring the cost of capital: at 20x forward P/E, Merck is priced for perfection, yet the R&D required to bridge the 2028 gap will compress margins. This isn't 'low-risk growth'; it's a high-stakes transition period masked by defensive beta.
"Keytruda biosimilars' potential FDA interchangeability could accelerate revenue loss before 2028, unpriced at 20x P/E."
Gemini, your M&A skepticism ignores Merck's track record--$11B Prometheus deal already bolsters oncology beyond Keytruda with LAG-3 combos. $17B FCF funds more. Bigger miss by all: Keytruda biosimilars seeking FDA interchangeability status could trigger payer switches pre-2028, compressing 40% of revenue faster than expected and justifying P/E contraction to 15x.
"Biosimilar interchangeability risk pre-2028 is underpriced and could force multiple compression before Winrevair revenue offsets Keytruda losses."
Grok just surfaced the real near-term threat: biosimilar interchangeability pre-2028 compresses Keytruda revenue faster than the 2028 cliff narrative suggests. That's material. But Grok also overstates Prometheus's impact—LAG-3 combos are early-stage, not proven revenue replacements. The $17B FCF is real, but if biosimilars hit before Winrevair scales, Merck faces simultaneous revenue contraction and pipeline execution pressure. That's the scenario the 20x multiple doesn't adequately price.
"Winrevair's path to $5B by 2028 and a 42% revenue share is optimistic; biosimilar risk and slower payer adoption could cause a larger-than-expected multiple contraction."
GroK's bullish view on Winrevair assuming a $5B+ revenue driver by 2028 and a 42% revenue share appears optimistic given HFpEF adoption, payer hurdles, and potential competition. Even with success, ramp and pricing stability are uncertain; a pre-2028 biosimilar surge and slower payer uptake could trigger a larger multiple compression than a plain 20x base.
The panel is bearish on Merck's current valuation, citing Keytruda's looming patent cliff, the uncertainty around Winrevair's market capture, and the potential acceleration of revenue compression due to biosimilars seeking FDA interchangeability status.
Winrevair becoming a $5B+ revenue driver by 2028, expanding the PAH market to $5B+ peak sales.
Accelerated revenue compression due to biosimilars seeking FDA interchangeability status for Keytruda before 2028.